Semaglutide Side Effects

Summary: Most semaglutide side effects are gastrointestinal, dose-dependent, and fade as the body adapts. A small set are serious and need prompt action: pancreatitis, gallbladder disease, kidney injury from dehydration, and signs of allergic reaction.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short version: most people on semaglutide get gastrointestinal side effects, most of those fade with time, and a small list of rare events are the ones that actually require attention. Nausea hits roughly 44% of patients at full weight-loss doses. Vomiting hits roughly 24 to 36%. Diarrhea about 30%, constipation about 24%. Almost everything else is either downstream of the GI effects or sits in the under-10% bucket ^[1][2][3].

This page covers every documented side effect of semaglutide across Ozempic, Wegovy, and Rybelsus, ordered by frequency. What is dose-dependent, what is reversible, what is persistent, when to push through, and when to call a doctor.

How semaglutide side effects work in one paragraph

Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, increases insulin secretion after meals, suppresses glucagon, and acts on appetite circuits in the hypothalamus and brainstem. The slowed stomach emptying explains most of the gut side effects. The appetite signaling explains the early satiety and food aversion. The brain pathways explain the fatigue and occasional mood shifts. Everything else is rare, mechanism-specific, or downstream of dehydration when GI effects get out of hand.

The frequency table

Numbers above pool data across Ozempic, Wegovy, Rybelsus, and the higher-dose Wegovy HD (7.2 mg) trials reported in the FDA labels and the STEP and SELECT programs ^{[1][2][3][4][5]}.

Gastrointestinal side effects: the big four

About 73% of patients on the 2.4 mg weight-loss dose report at least one GI adverse event ^[5]. Severity is mostly mild to moderate. About 4% report severe GI reactions. These are by far the most common reason people stop semaglutide.

Nausea

The signature side effect. Reported in roughly 44% of Wegovy users at full dose and around 20% of Ozempic users at lower diabetes doses. It clusters in the first 2 to 3 days after a dose increase and after the weekly injection itself. Most patients describe it as a low-grade queasiness that worsens with large meals, fatty meals, or strong food smells. Severe nausea is uncommon but does happen.

What helps in practice:

• Smaller meals, eaten slowly. The slowed stomach emptying does not tolerate full plates the way an untreated stomach does.
• Stop eating at the first sign of fullness, not at the last.
• Avoid fried, very fatty, or heavily spiced food during titration weeks.
• Bland carbs (toast, crackers, rice) and cold liquids tend to sit better than hot soups or rich proteins.
• Ginger tea or ginger candy has actual evidence behind it for nausea, not just folklore.
• Anti-nausea medication like ondansetron is often prescribed during the worst weeks if symptoms interfere with eating or work.

Vomiting

Reported in 24% at the 2.4 mg dose and as high as 36% at the 7.2 mg Wegovy HD dose ^[5]. Usually follows the nausea pattern. Vomiting after every dose, vomiting that prevents you from keeping liquids down, or vomiting for more than 48 hours is the line where you call your prescriber. Persistent vomiting drives dehydration, which is the single biggest mechanism behind semaglutide-associated kidney injury.

Diarrhea

Roughly 30% of patients ^[5]. Less common than nausea but more disruptive socially. Often peaks in the first month or after each dose increase. Most cases are mild and self-resolve. Loperamide is safe to use short-term. Severe or bloody diarrhea is not a normal side effect and warrants a call.

Constipation

Roughly 24% ^[5]. The flip side of slowed gut motility. Fiber, hydration, and a low-dose stool softener (docusate) or osmotic laxative (polyethylene glycol) usually handle it. Severe constipation, fecal impaction, and intestinal obstruction have all been reported postmarketing and are the reason fiber alone is not always enough. If you go more than 4 to 5 days without a bowel movement and feel abdominal distension, call your prescriber.

Abdominal pain, bloating, burping, reflux

Reported in 1 to 20% of patients depending on the symptom ^[5]. Mostly nuisance-level. Severe upper abdominal pain that radiates to the back is a different story (see pancreatitis below).

Injection site reactions

Reported in 1 to 10% of patients on the subcutaneous formulations (Ozempic, Wegovy) ^[5]. Includes redness, mild swelling, itching, induration (a small firm bump), and tenderness at the injection site. Almost always self-limited and gone within 48 hours.

Practical fixes:

• Rotate sites between abdomen, thigh, and upper outer arm.
• Let the pen sit at room temperature for 10 to 15 minutes before injecting. Cold semaglutide stings more.
• Inject at 90 degrees, push slowly, count to five before withdrawing.
• Do not rub the site afterward.

Hives, widespread rash, or any swelling involving the face, lips, tongue, or throat is allergic reaction, not a normal injection site reaction (see anaphylaxis below).

Headache, fatigue, dizziness

Headache is reported in up to 17% of trial participants, fatigue in up to 11%, dizziness in 1 to 10% ^[5]. Mechanisms are mixed. Some of it is the same central appetite signaling that drives the GI effects. Some of it is downstream of eating less and dehydration. Some of it is the body adapting to lower blood glucose excursions.

Hydration and salt intake fix most of the dizziness and a chunk of the fatigue. Caffeine still works, and many patients report needing less of it once appetite drops. Headaches that develop a new pattern or come with vision changes are not normal and need evaluation.

Hypoglycemia: only with insulin or sulfonylureas

Semaglutide by itself does not cause low blood sugar in people without diabetes. The FDA labels and Mayo monograph are explicit on this point ^[1][2]. The mechanism is glucose-dependent: semaglutide only stimulates insulin release when blood glucose is elevated.

The risk appears when semaglutide is combined with insulin, glipizide, glyburide, glimepiride, or other sulfonylureas. In type 2 diabetics on those combinations, hypoglycemia is very common (up to 29.8% in trials) ^[5]. Standard practice: when starting semaglutide, the prescriber usually reduces insulin or stops the sulfonylurea, then re-titrates based on glucose monitoring.

Symptoms to recognize: shakiness, sweating, confusion, fast heartbeat, hunger, blurred vision, slurred speech. Glucose tablets, juice, or honey fix it within minutes. Keep a source on you if you take insulin or a sulfonylurea alongside semaglutide.

Taste changes, dry mouth, and "Ozempic burps"

Patients describe coffee tasting bitter, food losing appeal, water tasting metallic, and an unpleasant sulfurous burp that follows fatty meals. Dysgeusia (altered taste) is listed as a common side effect in the FDA labels ^[1][2]. Dry mouth is listed under common GI adverse reactions ^[5].

The taste shifts are partly biological, partly downstream of the appetite changes. Coffee tastes worse to many semaglutide patients in the first few months and then normalizes for some. Food preferences often skew toward bland, light, plant-forward meals because heavy or rich food triggers nausea. Most of this is reversible: taste returns within weeks of stopping.

Burping that smells of rotten eggs is sulfur burps, caused by slowed transit of protein through the gut. It is harmless but unpleasant. Reducing red meat, eggs, garlic, and onions during titration usually fixes it. Bismuth subsalicylate (Pepto-Bismol) works in a pinch.

Body odor and urine changes

Reports of changed body odor and changed urine smell are common in patient forums and turn up in the secondary keyword searches. The clinical literature does not list either as a recognized adverse event in the FDA labels ^[1][2]. The most likely mechanisms are downstream:

• Reduced food intake plus weight loss increases fat metabolism and ketone production, which can change breath and sweat odor.
• Reduced fluid intake or dehydration from GI side effects concentrates urine, which makes it darker yellow and stronger-smelling.
• Some patients add high-protein or low-carb eating patterns when starting semaglutide, both of which independently shift body odor.

Drinking more water resolves most of the urine concentration issue. Yellow urine with no other symptoms is usually mild dehydration. Dark amber urine combined with reduced output, dizziness, or swelling is a sign of more serious dehydration and possible kidney involvement (see below).

Hair loss

Reported in up to 5.3% of patients in weight-loss trials versus 1% on placebo ^[5]. Almost always telogen effluvium, the diffuse shedding pattern that follows rapid weight loss, low energy intake, and any large metabolic shift. It is not unique to semaglutide. The same effect appears with bariatric surgery, low-calorie diets, and any GLP-1 that produces meaningful weight loss.

Most cases are mild, peak around month 3 to 6, and recover on their own with adequate protein, adequate calories, iron-replete status, and patience. The data shows most patients regrow the hair while still on semaglutide. Patchy or scarring hair loss is different and should be evaluated separately.

Pancreatitis

Acute pancreatitis is reported in 0.1 to 1% of semaglutide users ^[5]. The Wegovy label warns about it and instructs patients to stop the drug if it occurs ^[2]. Symptoms: severe, persistent upper abdominal pain that often radiates to the back, with nausea and vomiting. The pain does not improve with eating. It typically worsens over hours.

Pancreatitis on semaglutide requires emergency evaluation. Lipase and amylase are checked. Most cases are mild and resolve with bowel rest and IV fluids, but necrotizing and fatal cases have been reported. Patients with a history of pancreatitis are usually steered away from GLP-1 medications.

Gallbladder disease

Gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) are reported in 1 to 10% of patients on semaglutide ^[5]. The mechanism is partly the drug, partly the rapid weight loss. Any rapid weight loss raises gallstone risk because bile composition shifts. STEP-1 and SELECT both documented elevated gallbladder events in the semaglutide arms ^[3][4].

Symptoms: pain in the upper right abdomen, especially after fatty meals, often radiating to the right shoulder blade. Yellowing of the skin or eyes (jaundice), clay-colored stool, or fever change it from outpatient evaluation to emergency evaluation.

Thyroid C-cell tumor warning

Every semaglutide product carries a boxed warning about thyroid C-cell tumors. The basis is rodent data: semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in rats at clinically relevant exposures ^[1][2]. Whether this happens in humans is unknown. Long-term human surveillance has not, to date, shown an increased rate of medullary thyroid carcinoma in semaglutide users versus controls.

The label is explicit: do not use semaglutide if you or a first-degree relative has a personal history of medullary thyroid carcinoma, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Symptoms to report: a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.

Diabetic retinopathy worsening

In the SUSTAIN-6 cardiovascular trial in type 2 diabetics, semaglutide was associated with a higher rate of diabetic retinopathy complications than placebo. The proposed mechanism is the speed of glucose lowering rather than a direct retinal effect: any rapid improvement in glycemic control can transiently worsen pre-existing retinopathy. Patients with established diabetic retinopathy need a baseline eye exam before starting semaglutide and close monitoring during titration ^[1].

This is a diabetes-specific concern. The STEP weight-loss trials in non-diabetic patients did not show the same signal ^[3]. Sudden vision changes, blurry vision, or new floaters need urgent ophthalmology evaluation regardless.

Acute kidney injury

Kidney injury from semaglutide is almost always indirect. The mechanism is dehydration: severe nausea, vomiting, or diarrhea reduces fluid intake and increases fluid loss, which drops kidney perfusion, which causes prerenal acute kidney injury. Some cases have required hemodialysis ^[5]. Patients with pre-existing chronic kidney disease are at higher baseline risk.

Symptoms of kidney trouble: reduced urine output, swelling in feet and ankles, unusual fatigue, confusion, nausea independent of the GI side effects, shortness of breath. Hydration is the prevention. If you cannot keep liquids down for more than 24 hours, that is the moment to call your prescriber and probably pause the drug.

Allergic reactions and anaphylaxis

Mild allergic reactions (rash, hives) are reported in 1 to 10% of patients ^[5]. Anaphylaxis and angioedema are rare (0.01 to 0.1%) but life-threatening. Symptoms: swelling of the face, lips, tongue, or throat, trouble breathing, trouble swallowing, widespread hives, dizziness, or loss of consciousness. This is a 911 situation, not a wait-and-see situation. Stop semaglutide and do not restart without an allergist evaluation.

Suicidal ideation: the FDA monitoring story

Postmarketing reports of suicidal ideation prompted the FDA and EMA to investigate GLP-1 receptor agonists starting in 2023. Both agencies completed reviews. The FDA found no clear causal link in its analysis of the FAERS database, the active comparator studies, and the trial data, and did not require a new warning label. The class-effect language in the Drugs.com monograph reflects ongoing surveillance, not a confirmed signal ^[5].

In practice: depression and anxiety symptoms can appear during semaglutide treatment, including in patients with no prior history. Drivers include the metabolic shift, rapid weight loss, changes in eating patterns and social routines, and sleep changes. Patients with active depression or a history of suicidal ideation should be monitored closely. Any new suicidal thoughts are a reason to stop the drug and get evaluated.

Pulmonary aspiration during anesthesia

Semaglutide slows gastric emptying enough that residual food can remain in the stomach despite standard preoperative fasting. Cases of pulmonary aspiration during general anesthesia and deep sedation have been reported in GLP-1 users ^[5]. The American Society of Anesthesiologists now recommends holding semaglutide for one week before elective surgery requiring general anesthesia or deep sedation. Tell every surgeon and every anesthesia team you are on semaglutide.

Cardiovascular: the SELECT trial flipped the script

Worth mentioning because it changes the risk-benefit math. The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, nonfatal stroke) by 20% versus placebo over a mean 39.8 months of follow-up ^[4]. This is the basis for the FDA approval expanding Wegovy to reduce cardiovascular risk in adults with overweight or obesity and established cardiovascular disease.

So the cardiovascular column is genuinely net-positive in that population. Elevated heart rate (mean 1 to 4 beats per minute) is a known semaglutide effect ^[5], but the overall MACE benefit dominates.

Long-term side effects

Long-term data now extends to roughly 4 to 5 years across the SUSTAIN-6, STEP, and SELECT programs ^[3][4]. The picture so far:

• GI side effects do not appear to worsen with time. Most patients who tolerate the first 6 months tolerate the drug indefinitely.
• Hair loss, taste changes, and most fatigue resolve.
• The increased rate of gallbladder events persists, driven partly by the weight loss itself.
• The thyroid C-cell tumor concern remains theoretical in humans after years of postmarketing surveillance, but the boxed warning stays.
• Bone density and fracture data are still being collected. The current FDA labels note increased fractures of the hip and pelvis in women and patients aged 75 and older ^[5]; this is plausibly a downstream effect of rapid weight loss and reduced muscle mass rather than a direct drug effect.
• No new cardiovascular signals have appeared. SELECT showed net benefit in that population.

The honest answer on long-term safety: the data through about 4 years looks reassuring. Beyond that, surveillance continues.

Sex drive and sexual side effects

Direct sexual side effects are not listed in the FDA labels for Ozempic, Wegovy, or Rybelsus ^[1][2]. Patient reports run in both directions. Some report lower libido during the worst nausea weeks (unsurprising), some report higher libido after meaningful weight loss (also unsurprising). There is no controlled trial showing semaglutide directly changes sex drive in either direction.

A small number of male patients have reported erectile dysfunction. Mechanisms could include vascular changes during rapid weight loss, hormonal shifts (weight loss in obese men typically raises testosterone), or coincidence. There is no evidence semaglutide changes penis size or causes shrinkage; that claim is a social media artifact, not a clinical finding.

Mood swings

Mood changes are reported under "anxiety" in 1 to 10% of patients in some semaglutide trials ^[5]. Patient experience tends to involve irritability during the worst GI weeks, low mood when food no longer feels rewarding, and a positive mood shift after meaningful weight loss. None of this is unique to semaglutide; any large metabolic and behavioral shift produces it.

If mood symptoms are pronounced, predate semaglutide, or include suicidal thoughts, this needs separate clinical attention. Do not assume the drug is the only variable.

Sex-specific patterns: females versus males

The trials did not show large sex-based differences in overall side effect profile. Two patterns are worth flagging:

• Women on semaglutide have reported menstrual irregularity and changes in oral contraceptive absorption in case reports. The FDA labels do not list menstrual changes as adverse events, but rapid weight loss is a known driver of cycle changes. If you rely on oral contraceptives, the slowed gastric emptying is a relevant consideration for backup contraception during titration.
• Hip and pelvic fractures showed up more in women than men in pooled data ^[5], particularly in women aged 75 and over. This is the strongest sex-specific signal in the safety data.

Beyond those, side effect rates by sex track each other closely.

When to push through, when to pause, when to stop

Push through (mild, self-limited, expected):

• Mild to moderate nausea in the first 2 weeks after a dose increase
• Constipation responding to fiber, hydration, or stool softeners
• Diarrhea responding to loperamide
• Injection site redness that resolves in 24 to 48 hours
• Mild headache or fatigue that improves with hydration
• Taste changes
• Mild hair shedding starting in month 3 to 6

Pause and call your prescriber:

• Vomiting that prevents you from keeping liquids down for more than 24 hours
• Diarrhea persisting more than 5 days
• Sudden severe abdominal pain (rule out pancreatitis or gallbladder)
• Right upper quadrant pain after meals, jaundice, clay-colored stool (gallbladder)
• Significant decrease in urine output, swelling, confusion (kidney)
• New or worsening vision changes (especially in diabetics)
• Mood changes including any suicidal thoughts

Stop and seek emergency care:

• Swelling of face, lips, tongue, throat; trouble breathing or swallowing (anaphylaxis)
• Persistent severe abdominal pain radiating to the back (pancreatitis)
• Chest pain, severe shortness of breath
• Signs of severe dehydration (no urine, severe dizziness on standing, fainting)
• New lump or swelling in the neck, hoarseness, trouble swallowing (thyroid)

Practical dose-management strategies

Almost every semaglutide side effect responds to one of three levers: titration speed, dose level, and timing.

• Slow the titration. The standard schedule moves up every 4 weeks. If side effects spike, holding the current dose for an extra 4 weeks before stepping up is a recognized strategy and does not compromise long-term outcomes in trial data.
• Stay at a lower maintenance dose. Not every patient needs to reach 2.4 mg or 7.2 mg to get a benefit. Many do well at 1.0 mg or 1.7 mg.
• Move the injection day. Some patients find side effects align with the first 48 hours after injection. Shifting from a Monday injection to a Friday or Saturday injection lets the worst day land on a weekend.
• Coordinate meals around the injection. Lighter, smaller, blander meals in the 48 hours after the dose reduce the load on a slowed-emptying stomach.
• Hydrate aggressively. The single most underrated intervention. Most of the dizziness, headache, fatigue, and kidney risk is dehydration.

What semaglutide is not responsible for

A few things commonly attributed to semaglutide that the clinical data does not support:

• Loose skin (this is rapid weight loss, not the drug)
• "Ozempic face" (loss of facial fat from weight loss, not a drug effect)
• Muscle loss specifically caused by the drug (any rapid weight loss without adequate protein and resistance training causes muscle loss; semaglutide is not unique here)
• Permanent metabolic damage (no clinical evidence supports this claim)
• Cancer in humans (no signal in human data; rodent thyroid C-cell tumors are a separate issue covered above)

Frequently asked questions

How long after a semaglutide injection do side effects start?

GI side effects typically start within 12 to 48 hours after the injection and peak in the first 2 to 3 days. The drug stays in the system about a week, so a baseline level of side effects can persist throughout the dosing interval.

What are the most common side effects of Ozempic?

Nausea, vomiting, diarrhea, abdominal pain, and constipation. These also dominate the side effect lists for Wegovy and Rybelsus because the active ingredient is the same.

What is the biggest side effect of Ozempic?

Nausea by frequency, affecting up to 20% at diabetes doses and up to 44% at weight-loss doses. By severity, the rare events to watch for are pancreatitis, gallbladder disease, and dehydration-driven kidney injury.

Does semaglutide cause dry mouth?

Yes, dry mouth is listed as a common side effect in the FDA labels. It usually responds to better hydration and resolves with time.

Why does coffee taste bad on semaglutide?

Dysgeusia (altered taste) is a recognized side effect. Coffee specifically tends to taste more bitter or metallic. The change is usually temporary and resolves within weeks to months of stopping the drug.

Does semaglutide make your urine smell or look different?

Not directly. Concentrated, darker-yellow, stronger-smelling urine on semaglutide is almost always mild dehydration from reduced fluid intake. Drinking more water resolves it.

Should I pause semaglutide if side effects get bad?

For severe vomiting, severe diarrhea, severe abdominal pain, signs of allergic reaction, signs of dehydration, or any suicidal thoughts: yes, and call your prescriber. For mild to moderate GI symptoms, slowing the titration or holding the current dose is usually preferred over stopping outright.

What are the long-term side effects of Ozempic?

Through 4 to 5 years of follow-up in the SUSTAIN, STEP, and SELECT programs, no new safety signals have emerged. GI effects do not worsen. Gallbladder risk persists. The boxed warning on thyroid C-cell tumors remains theoretical in humans.

Does semaglutide affect sex drive?

Direct sexual side effects are not listed in FDA labels. Patient reports run both ways: some report lower libido during severe nausea weeks, some report higher libido after weight loss.

Are mood swings a side effect of semaglutide?

Anxiety is listed in 1 to 10% of patients. Larger mood changes are reported anecdotally but not consistently across trials. New suicidal thoughts on the drug are a reason to stop and seek evaluation.

Does semaglutide affect women differently than men?

Overall side effect rates are similar. Two patterns: hip and pelvic fractures appear more in women, especially over age 75; and rapid weight loss can shift menstrual cycles and may affect oral contraceptive absorption during titration.

How do I track semaglutide side effects?

A simple weekly log works: injection date, dose, day-by-day notes on nausea, appetite, bowel patterns, weight, energy, and any new symptoms. Bring it to every prescriber visit. Patterns are easier to spot in writing than from memory.

What this article does not cover

This is the comprehensive overview. Deep dives on specific topics, including detailed pancreatitis management, gallbladder risk in rapid weight loss, hair loss recovery protocols, anesthesia and surgery scheduling on GLP-1s, and the SELECT cardiovascular results in full, have their own dedicated pages on this site. Use the search or sidebar to find them.